Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.
The aim of this study was to investigate which principal human cytochrome P450 (CYP450) enzymes are affected by artemisinin and to what degree the artemisinin derivatives differ with respect to their respective induction and inhibition capacity. Seventy-five healthy adults were randomized to receive therapeutic oral doses of artemisinin, dihydroartemisinin, arteether, artemether or artesunate for 5 days (days 1-5). A six-drug cocktail consisting of caffeine, coumarin, mephenytoin, metoprolol, chlorzoxazone and midazolam was administered orally on days -6, 1, 5 and 10 to assess the activities of CYP1A2, CYP2A6, CYP2C19, CYP2D6, CYP2E1 and CYP3A, respectively. Four-hour plasma concentrations of parent drugs and corresponding metabolites and 7-hydroxycoumarin urine concentrations were quantified by liquid chromatography-tandem mass spectrometry. The 1-hydroxymidazolam/midazolam 4-h plasma concentration ratio (CYP3A) was increased on day 5 by artemisinin [2.66-fold (98.75% CI: 2.10-3.36)], artemether [1.54 (1.14-2.09)] and dihydroartemisinin [1.25 (1.06-1.47)] compared with day -6. The S-4'-hydroxymephenytoin/S-mephenytoin ratio (CYP2C19) was increased on day 5 by artemisinin [1.69 (1.47-1.94)] and arteether [1.33 (1.15-1.55)] compared with day -6. The paraxanthine/caffeine ratio (CYP1A2) was decreased on day 1 after administration of artemisinin [0.27 (0.18-0.39)], arteether [0.70 (0.55-0.89)] and dihydroartemisinin [0.73 (0.59-0.90)] compared with day -6. The alpha-hydroxymetoprolol/metoprolol ratio (CYP2D6) was lower on day 1 compared with day -6 in the artemisinin [0.82 (0.70-0.96)] and dihydroartemisinin [0.83 (0.71-0.96)] groups, respectively. In the artemisinin-treated subjects this decrease was followed by a 1.34-fold (1.14-1.58) increase from day 1 to day 5. These results show that intake of artemisinin antimalarials affect the activities of several principal human drug metabolizing CYP450 enzymes. Even though not significant in all treatment groups, changes in the individual metrics were of the same direction for all the artemisinin drugs, suggesting a class effect that needs to be considered in the development of new artemisinin derivatives and combination treatments of malaria.
Asimus
Sara
S
Unit for Pharmacokinetics and Drug Metabolism, Department of Pharmacology, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden.
Elsherbiny
Doaa
D
Hai
Trinh N
TN
Jansson
Britt
B
Huong
Nguyen V
NV
Petzold
Max G
MG
Simonsson
Ulrika S H
US
Ashton
Michael
M
D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000494:pharmacology*; D037621:Artemisinins / Q000494:pharmacology*; D002110:Caffeine / Q000097:blood / Q000493:pharmacokinetics; D002753:Chlorzoxazone / Q000097:blood / Q000493:pharmacokinetics; D003374:Coumarins / Q000097:blood / Q000493:pharmacokinetics / Q000652:urine; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008617:Mephenytoin / Q000097:blood / Q000493:pharmacokinetics; D008790:Metoprolol / Q000097:blood / Q000493:pharmacokinetics; D008874:Midazolam / Q000097:blood / Q000493:pharmacokinetics; D008875:Middle Aged
D000962:Antimalarials; D037621:Artemisinins; D003374:Coumarins; D002110:Caffeine; D003577:Cytochrome P-450 Enzyme System; C030123:coumarin; D008790:Metoprolol; D002753:Chlorzoxazone; D008617:Mephenytoin; D008874:Midazolam